Any program of therapy for clinically advanced nonsmall cell lung cancer (NSCLC) that would increase the incidence of local tumor control and decrease the likelihood of distant metastatic disease would be of obvious benefit. The objective of neoadjuvant therapy is to eradicate the primary tumor and micrometastatic disease. In the past 10 years, many trials have been com- 
Any program of therapy for clinically advanced nonsmall cell lung cancer (NSCLC) that would increase the incidence of local tumor control and decrease the likelihood of distant metastatic disease would be of obvious benefit. The objective of neoadjuvant therapy is to eradicate the primary tumor and micrometastatic disease. In the past 10 years, many trials have been completed to evaluate neoadjuvant therapy and they have included sequential chemoradiotherapy, concurrent chemoradiotherapy, chemotherapy/surgery, and chemoradiation/surgery. These N2 disease, as patients who have microscopic nodal metastasis found at the time of surgical resection have a 20 to 30% 5-year survival r4te. However, patients in whom nodal metastases are detected by mediastinoscopy have approximately a 10% chance of surviving 5 years. The 5-year survival rate for nodal metastases that are evident on routine chest radiographs is less than 5% with surgical therapy. Surgery alone will not improve survival. For many years, the standard of therapy for clinically advanced or inoperable NSCLC has been radiation therapy, and the 5-year survival approximates 5 to 10%. Any program of therapy that would increase the incidence of local tumor control and decrease the occurrence of distant metastatic disease would be of obvious benefit. RATIONALE FOR NEOADJUVANT THERAPY Radiation can sterilize the tumor bed, and its use in a preoperative mode when the blood supply is intact is appealing. Tumor cells are more sensitive to radiation at a higher oxygen tension and this would apply to the highly vascularized peripheral border of an invasive lung cancer. The advantages to be gained from radiation therapy would include the following: (1) a decrease in the size of the tumor, facilitating resection or possibly down-staging the lesion; (2) the ability to ensure a complete resection; (3) minimizing the seeding of tumor cells by surgical manipulation; and (4) sterilization of the tumor bed. Disadvantages would be that not all of the tumor is in the radiation field, postoperative complications are increased, surgery is delayed even if the tumor is not radio-sensitive, and the tumor is not totally ablated.
Chemotherapy is appealing, with the opportunity to treat micrometastatic disease and, also, produce regression of primary lesion. Larger clinical trials have shown that the most active regimens contain cisplatin and produce response rates of approximately 25% in stage IV disease.
Combining chemotherapy and radiation with surgical resection is appealing in that the micrometastatic disease can possibly be eradicated by the chemotherapy, and decreasing the bulk of the tumor by radiation and chemotherapy may permit a more complete surgical resection.
The disadvantages of any neoadjuvant program, either singularly or in combination, include toxic reactions resulting in morbidity or death, a delay in surgical therapy to control local disease, an increase in operative complication and mortality rates, and a failure to achieve survival rates better than those of surgery or radiation alone.
TREATMENT SEQUENCE
Six randomized trials have compared radiotherapy alone with chemotherapy followed by radiation therapy. Survival results of these trials are summarized in Table 1 .
These studies have confirmed that combination therapy is feasible and some showed survival advantages. The study by Dillman et all demonstrated a significant survival advantage for the chemoradiotherapy arm of the study. Analysis of this data also determined the need for improved local control, and this finding would suggest surgical resection as the possible method for better local control of the tumor. A large intergroup trial that compared the higher response rate, resection rate, and freedom from progression were observed in the chemoradiation arm after a median follow-up of 3 years. These differences were all statistically significant. LCSG 85211 was a study to evaluate concurrent chemotherapy and radiation therapy in patients with NSCLC who were judged to have technically unresectable disease and in whom it was believed there would most likely be gross residual disease. Chemotherapy consisted of cisplatin and fluorouracil and radiation was 3,000 cGy in 15 fractions. Operative mortality was 7% (4/54) and only 29 patients had a complete resection. Median survival of all patients in the series was 13 months.
LCSG 83112 evaluated 39 patients in a phase 2 study who were treated with chemotherapy (cisplatin, doxorubicin, and cyclophosphamide) and chest radiation (3,000 cGy in 10 fractions). Only those patients with regression of the primary tumor (49%, 19/39) were considered eligible for surgery. There was no operative mortality and 13 complete resections were accomplished. Median survival was 11 months and the 2-year projected survival was 8%.
DISCUSSION
Review of these trials that have been conducted over the past several years indicates that neoadjuvant therapy is feasible and generally well tolerated. Most of the chemotherapeutic agent is delivered to the patient and toxic deaths are minimal. There is greater than a 50% response rate and, in approximately 20% of patients who have undergone resection (15% of patients entering study), the tumor is totally sterilized. A greater incidence of a complete resection is achieved and this factor theoretically enhances long-term survival. Survival rates are higher than the reported historical controls for this group of patients. The technical aspects of the surgical resection can be difficult and morbidity is increased. However, surgical mortality is comparable to surgical resection alone in patients with clinically advanced lung cancer.
A major question remains whether neoadjuvant therapy for clinically advanced lung cancer can be considered the standard of care. There are those who believe that these patients should be treated only in committee-approved phase 2 or phase 3 protocols and others who believe that this can be a standard of care in the community. Based on my experience, I believe that a patient with proven metastatic disease to mediastinal lymph nodes, invasion of the mediastinum, or T4 extension of the tumor should have neoadjuvant therapy followed by surgery. Prior to the institution of these types of treatment programs, resection rates were 50% and the "open and close" thoracotomy was the order of the day. An improvement of survival from 15% to 30% is a 100% increase and for our patients, the benefits of neoadjuvant therapy seem to have been well established.
The recently reported meta-analysis of neoadjuvant therapy supports our position.2 The thoracic oncologic community awaits the results of ongoing phase 3 trials'3 that will compare neoadjuvant therapy and surgical resection for local control to chemotherapy and high-dose radiation for local control. In the mean time, additional phase 2 trials will be required to test new agents such as paclitaxel (Taxol) and to determine which preoperative regimens are appropriate for study in phase 3 trials.
